NEW YORK (GenomeWeb) – Biogazelle today announced a research collaboration with Isis Pharmaceuticals to identify and validate novel drug targets. 

The collaboration is aimed at treatments for colon, liver, and lung cancer. Isis will provide Biogazelle with access to its antisense platform for the large-scale validation of therapeutic long non-coding RNA targets from Biogazelle's target identification pipeline. 

Financial and other details of the deal were not disclosed. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

Nov
02
Sponsored by
Qiagen

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Dec
05
Sponsored by
Agilent Technologies

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.